RXi Pharmaceuticals is a clinical-stage company developing therapeutics based on its self-delivering RNAi (sd-rxRNA®) platform and Samcyprone, a topical immunomodulator. Co.'s clinical development programs include RXI-109, an sd-rxRNA for the treatment of dermal and ocular scarring, and Samcyprone, for the treatment of warts. Co.'s development programs also include cell-based cancer immunotherapy. Co.'s RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its topical immunotherapy agent, Samcyprone, treats diseases by inducing, enhancing or suppressing an immune response in the skin. The RXII average annual return 10 years is shown above.
The Average Annual Return on the RXII average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RXII average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RXII average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|